Need professional-grade analysis? Visit stockanalysis.com
$27.93B
N/A
231
N/A
Duality Biotherapeutics Inc (9606) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD311.80, up 0.39% from the previous close.
Over the past year, 9606 has traded between a low of HKD176.50 and a high of HKD510.00. The stock has gained 42.6% over this period. It is currently 38.9% below its 52-week high.
Duality Biotherapeutics Inc has a market capitalization of $27.93B.
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Side-by-side comparison against top Healthcare peers.